A final piece of the puzzle is sought in the assessment if biomarker and metabolomics profiles in clinical cases and MZ twins discordant for aggression. Given the fact that human aggressive behaviour is heterogeneous and that most effective therapeutic agents only work on the serotonergic system a comprehensive study of the role of the amino acid neurotransmitters (including both their precursors and degradation metabolites) and peptide-based neurotransmitters is warranted. In addition to this biomarker approach, ACTION will include a metabolomics approach and the platforms we are measuring include amines, organic acids and steroids.
